ABSTRACT INFORMATION

Participants are invited to submit abstracts under any of the categories listed below. Abstracts
will be selected by the Scientific Committee . Please indicate your preference in the space
provided when submitting your abstract.

If you have a Problem with submitting your Abstract Please Contact :

Mohamed Arafat at : mohamed@mspfd2011 .org

Please, click here to start your

abstract submission.

Abstract submission rules

Please follow these rules carefully. Failure to comply with abstract submission rules will result
in your abstract not being accepted for review.
**Please note that the rules set out below apply to Poster/Platform abstract submission only.
Invited speakers should refer to instructions provided directly from the Congress Secretariat
for the submission of abstracts for invited lectures.

• Submission Rules
• Content Rules

Submission Rules

1. Abstracts will not be accepted unless they are submitted according to the rules,
instructions and format described and received by the Congress Secretariat on or
before midnight, 7 February 2011 . Late abstracts will NOT be accepted.
2. All abstract submissions for Poster/Platform presentations must be conducted via the
on-line abstract submission system at http://www.mspfd2011.org The transmission of
abstracts via fax and e-mail is not acceptable.
3. All abstracts should be written, submitted and presented in English only.
4. Abstracts should be no longer than 250 words (this limit excludes the abstract title,
authors and institutions).
5. The first name in each abstract should be that of the presenting author.
6. Submission of more than three abstracts by the same first author is not permitted.
7. Please note that invited speakers may submit abstracts for consideration for
platform/poster sessions.
8. Institution information should be provided for all authors. Include institution, city,
state/province and country but do not include department, division, laboratory, etc.
9. Abstracts should be structured in 4 sections:
Purpose
Method
Results
Conclusion
The "Purpose" section should indicate the objectives of the work being presented. The
"Method" section should describe study material or subjects (e.g. number and type of
patients), intervention and evaluation procedures. The "Results" section should
summarize the main findings. Wherever possible, give numerical values, including
 means with SD or SEM, and statistical significance or confidence intervals. The
"Conclusion" section should state briefly the conclusions reached in the work.
10. Figures, tables and other illustrations should not be included in abstracts.
11. Where appropriate, please name the ethics committee that has approved the study. If
you do not have an ethics system in your country/institution, please state this.
12. If the work was supported by funds provided by a commercial organization this should
be stated in a short acknowledgment at the end of the abstract. Other sources of
funding may be acknowledged in the same way.
13. The abstract submission system allows authors to amend their abstract before final
submission for review up until the abstract submission deadline. Amendments to
abstracts will not be permitted after the deadline.
14. Authors will be notified in writing whether or not their abstract has been approved by
the Scientific Advisory Committee (SAC) by 7 February 2011 Once an abstract has
been approved, the presenting author must register for the Congress for final abstract
acceptance. Abstracts will only receive final acceptance if the presenting author has
registered for the entire Congress.
15. Instructions for both platform and poster presentations will be made available with
notices of acceptance.
16. All abstracts accepted for presentation at the congress will be published, subject to
editorial review, in the congress abstract book. Each participant will receive a copy
free of charge.

Content Rules

1. Submission of abstracts describing data that have previously been published in any
scientific journal is not permitted.
2. Multiple submission of abstracts describing different components of the same study is
not appropriate. All findings generated from the same study should be included in a
single abstract.
3. Abstracts containing single case reports will not usually be accepted, unless the report
is of outstanding scientific or clinical interest because of the uniqueness of the findings
or the sophistication of the investigations.
4. Abstracts containing data considered to be insufficiently informative will not be
accepted.
5. Use a concise title that indicates the content of the abstract. The title should not
exceed 240 characters. Avoid using abbreviations in the title.
6. For intervention studies (for example, therapeutic trials), type of design (prospective or
retrospective, controlled or uncontrolled, randomized or observational, open vs. single-
blind vs. double-blind), dosages, assessment methods and duration of follow-up should
be specified.
7. Non-proprietary names of drugs must be used throughout. If results are considered to
be specific for a given proprietary product (for example, bio-equivalence studies), the
non-proprietary name must still be used, followed by the proprietary name and the
name of the manufacturers in brackets.
8. Abbreviations should be used sparingly. For words that are abbreviated, use the whole
term the first time, followed by the standard abbreviation in parenthesis.
9. References should be used sparingly. They should be included within the text in
brackets. For journals, mention first author "et al" followed by the name of the journal
as abbreviated in the Index Medicus, year, volume number and inclusive pages (i.e.
Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author "et al",
editor, title, publisher, city of publication, year and inclusive pages (i.e. Levy RH et al.
In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).
Submission of an abstract automatically implies acknowledgment that the work described was
conducted in accordance with current ethical standards and regulations in biomedical
research. Failure to adhere to these standards will result in rejection of the abstract